Clinical trials: Acute Stroke
Ischemic Stroke, Ischemia
Biomarkers of Acute Stroke in Clinic
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic…
- Conditions
- Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack
- Trial name
- BASIC (NCT03897478)
- Testing
- ISCDX blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Ischemia Care LLC
Acute Ischemic Stroke
SUMMIT RISE Study of Acute Ischemic Stroke Patients
SUMMIT RISE Study of Acute Ischemic Stroke Patients
- Trial name
- NCT07436156
- Testing
- Route 92 Medical Reperfusion Systems
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Route 92 Medical, Inc.
Acute Stroke
Cytoflavin in Combination With Reperfusion in Stroke Patients
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment…
- Trial name
- NCT05297851
- Testing
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Delirium, Stroke
Impact of Neuromonitoring During Cardiac Procedures
Through a series of sequential analyses, retrospective database exploration looking for linkages and associations between the use of processed electroencephalogram (EEG) and/or cerebral saturation monitoring and patient outcomes…
- Conditions
- Delirium, Stroke, Acute Kidney Injury
- Trial name
- NCT02681731
- Where
- United States
- Volunteers
- 250,000 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Acute Ischemic Stroke, Ischemic Stroke
Zeit Alert for Stroke at Home (ZASH) Protocol
This is a single-arm, observational, feasibility study to evaluate if the Halo Alert System can be used in the future to detect stroke events in individuals at risk for stroke wearing the Halo Alert System overnight.
- Conditions
- Acute Ischemic Stroke, Ischemic Stroke, Stroke
- Trial name
- ZASH (NCT05669456)
- Testing
- Halo Alert System
- Volunteers
- 300 people
- Sponsor
- Zeit Medical, Inc.
Transcranial Bone Marrow Injection, RK-4
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
An open-label, blinded Ib/IIa study investigating the treatment of acute large hemispheric infarction by transcranial bone marrow injection of RK-4 injection For subjects with acute large hemispheric infarction who are…
- Conditions
- Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke
- Trial name
- NCT07166380
- Testing
- RK-4 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
- Trial name
- NCT00499902
- Testing
- alfimeprase
- Where
- 22 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- ARCA Biopharma, Inc.
Acute Ischemic Stroke
Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)
To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous…
- Trial name
- TRON1-Japan (NCT02964702)
- Testing
- Thrombectomy Device T-01
- Where
- 13 sites in Japan
- Volunteers
- 50 people
- Sponsor
- JIMRO Co., Ltd.
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.
Acute Ischemic Stroke
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner.
- Trial name
- NCT04984577
- Testing
- Compound Edaravone Injection-Low dose, Compound Edaravone Injection-High dose, Edaravone Injection
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Stroke
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.
- Trial name
- CERE-LYSE-1 (NCT00840671)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 15 sites in Austria, Croatia and 3 more
- Volunteers
- 119 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Ischemic Stroke
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS). This study consists of 2 cohorts, Cohort A and Cohort B.
- Trial name
- Revive (NCT05953480)
- Testing
- Redasemtide
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 680 people
- Sponsor
- Shionogi
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.
Acute Ischemic Stroke
A Phase 1b Study to Assess the Safety and Tolerability of AB126 Neural Exosomes in Patients With Moderate to Severe Acute Ischemic Stroke
The goal of this clinical trial is to learn if AB126, an investigational treatment made from neural exosomes, is safe and well tolerated when given to adults with moderate to severe acute ischemic stroke (AIS) who have undergone…
- Trial name
- NEXIS (NCT07813130)
- Testing
- AB126 Neural Exosomes Intravenous Injection
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Aruna Bio, Inc.
AIS
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke
- Trial name
- NCT07520565
- Testing
- BXOS110
- Where
- 9 sites in China
- Volunteers
- 1,112 people
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
Acute Ischemic Stroke
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute…
- Trial name
- ACTION (NCT01955707)
- Testing
- natalizumab
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Biogen
Intracerebral Hemorrhage, Brain Hemorrhage
PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in subjects with intraventricular…
- Conditions
- Intracerebral Hemorrhage, Brain Hemorrhage, Intraventricular Hemorrhage
- Trial name
- PRONTO (NCT04178746)
- Testing
- Artemis Neuro Evacuation Device
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Penumbra Inc.
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients
The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure.
- Trial name
- NCT06733246
- Testing
- Aspiration 0
- Where
- Germany
- Volunteers
- 132 people
- Sponsor
- Ceretrieve Ltd.